<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Lead aVR</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->11/18/2011</div></div><div class="card__content"><h1 id="ecg-lead-avr">ECG: Lead aVR</h1>
<p><strong>Lead avR can provide some unique insight into 5 different conditions:</strong></p>
<ol>
<li>Acute MI</li>
<li>Pericarditis</li>
<li>Tricyclic antidepressants (TCA) and TCA-like overdose</li>
<li>AVRT in narrow complex tachycardias</li>
<li>Differentiating VT from SVT with aberrancy in wide complex tachycardias</li>
</ol>
<h2 id="acute-myocardial-infarction">Acute myocardial infarction</h2>
<p><strong>ST Elevation &gt;1.5 mm in aVR</strong></p>
<p><img src="https://aliemcards.netlify.com/media/ecg-lead-avr_image-1.png" alt="Example of ST elevation"></p>
<ul>
<li>Suggests left main coronary artery (LMCA), left anterior descending (LAD), or 3-vessel coronary disease</li>
<li>LMCA occlusion has a high mortality and often refractory to thrombolytics.</li>
<li><strong>aVR ST elevation in ACS patients:</strong> Independent predictor of recurrent ischemic events in-hospital, heart failure, and death </li>
</ul>
<h2 id="pericarditis">Pericarditis</h2>
<p><strong>PR elevation in aVR</strong></p>
<p><img src="https://aliemcards.netlify.com/media/ecg-lead-avr_image-2.png" alt="Example of PR elevation"></p>
<p>Suggests subepicardial atrial injury from pericardial inflammation</p>
<p><strong>Multilead ST elevation:</strong> </p>
<ul>
<li>Differential diagnosis includes ACS vs pericarditis </li>
<li>Concurrent PR elevation in aVR suggests pericarditis instead of ACS. </li>
</ul>
<h2 id="tricyclic-antidepressant-tca-tca-like-overdose">Tricyclic antidepressant (TCA) &amp; TCA-like overdose</h2>
<p><strong>Prominent R wave in aVR</strong></p>
<p><img src="https://aliemcards.netlify.com/media/ecg-lead-avr_image-3.png" alt="Example of a prominent R wave"></p>
<ul>
<li>Classic ECG findings of TCA overdose:<ul>
<li>Sinus tachycardia</li>
<li>Widened QRS and QTc interval</li>
<li>Right axis deviation 130-170 degrees</li>
<li>Prominent terminal R wave in aVR</li>
</ul>
</li>
<li>Predictor of arrhythmia (<a href="http://www.ncbi.nlm.nih.gov/pubmed/12974977">Buckley et al. Crit Care, 2003</a>):<ul>
<li>R/S ratio in aVR &gt;0.7 (PPV 46%, NPV 95%)</li>
</ul>
</li>
</ul>
<h2 id="avrt-in-wolff-parkinson-white-wpw-">AVRT in Wolff-Parkinson-White (WPW)</h2>
<p><strong>Atroventricular reentry tachycardia</strong></p>
<ul>
<li>ST elevation in aVR in narrow complex tachycardia</li>
<li>Narrow complex tachycardia ddx:<ul>
<li>AV node reentry tachycardia </li>
<li>AV reentry tachycardia</li>
<li>Atrial tachycardia</li>
</ul>
</li>
<li>ST elevation in aVR suggestive more of AVRT in WPW (sensitivity 71%, specificity 70%)</li>
</ul>
<h2 id="vereckei-criteria-vt-versus-svt-in-wide-complex-tachycardia">Vereckei criteria: VT versus SVT in wide complex tachycardia</h2>
<p><strong>Vereckei criteria:</strong> </p>
<ul>
<li>Asks 4 questions. </li>
<li>More sensitive and specific to detect ventricular tachycardia (VT) than Brugada criteria.</li>
<li><p><strong>Criteria looks ONLY at lead aVR</strong> (if answer is yes, then VT):</p>
</li>
<li><p>Is there an initial R wave?</p>
</li>
<li>Is there a r or q wave &gt;40 msec? (&gt;1 small box width)</li>
<li>Is there a notch on the descending limb of a negative QRS complex?</li>
<li>Measure the voltage change in the first (vi) and last 40 msec (vt). Is vi / vt &lt;1?</li>
</ul>
<p><img src="https://aliemcards.netlify.com/media/ecg-lead-avr_image-4.png" alt="Example of VT vs SVT"></p>
<table>
<thead>
<tr>
<th>Criteria</th>
<th align="center">Sensitivity</th>
<th align="center">Specificity</th>
<th align="center">PPV</th>
<th align="center">NPV</th>
</tr>
</thead>
<tbody><tr>
<td>Brugada</td>
<td align="center">89%</td>
<td align="center">73%</td>
<td align="center">92%</td>
<td align="center">67%</td>
</tr>
<tr>
<td>Verecki</td>
<td align="center">97%</td>
<td align="center">75%</td>
<td align="center">93%</td>
<td align="center">87%</td>
</tr>
</tbody></table>
<p>(<a href="http://www.ncbi.nlm.nih.gov/pubmed/18180024">Vereckei et al, Heart Rhythm 2008</a>)</p>
<h2 id="references">References</h2>
<ul>
<li>Kireyev D et al.Clinical utility of aVR-The neglected electrocardiographic lead. Ann Noninvasive Electrocardiol. 2010;15(2):175-80. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20522059">PubMed</a>]</li>
<li>Riera AR et al.Clinical value of lead aVR. Ann Noninvasive Electrocardiol. 2011 Jul;16(3):295-302. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21762258">PubMed</a>]</li>
<li>Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. 2008 Jan;5(1):89-98. doi: 10.1016/j.hrthm.2007.09.020. Epub 2007 Sep 20. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18180024">PubMed</a>]</li>
<li>Buckley NA et. al.The limited utility of electrocardiography variables used to predict arrhythmia in psychotropic drug overdose.Crit Care. 2003 Oct;7(5):R101-7. Epub 2003 Aug 18. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12974977">PubMed</a>]</li>
<li>Williamson K et al. Electrocardiographic applications of lead aVR. Am J Emerg Med. 2006 Nov;24(7):864-74. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17098112">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"ecg-lead-avr","title":"Lead aVR","authors":["Michelle Lin, MD"],"categories":[{"slug":"cardiovascular","name":"Cardiovascular"},{"slug":"ecg","name":"ECG"}],"created":"2011/11/18","updated":null,"body":"\n# ECG: Lead aVR\n\n**Lead avR can provide some unique insight into 5 different conditions:**\n\n1. Acute MI\n2. Pericarditis\n3. Tricyclic antidepressants (TCA) and TCA-like overdose\n4. AVRT in narrow complex tachycardias\n5. Differentiating VT from SVT with aberrancy in wide complex tachycardias\n\n## Acute myocardial infarction\n\n**ST Elevation \u003e1.5 mm in aVR**\n\n![Example of ST elevation](https://aliemcards.netlify.com/media/ecg-lead-avr_image-1.png)\n\n- Suggests left main coronary artery (LMCA), left anterior descending (LAD), or 3-vessel coronary disease\n- LMCA occlusion has a high mortality and often refractory to thrombolytics.\n- **aVR ST elevation in ACS patients:** Independent predictor of recurrent ischemic events in-hospital, heart failure, and death \n\n## Pericarditis\n\n**PR elevation in aVR**\n\n![Example of PR elevation](https://aliemcards.netlify.com/media/ecg-lead-avr_image-2.png)\n\nSuggests subepicardial atrial injury from pericardial inflammation\n\n**Multilead ST elevation:** \n\n- Differential diagnosis includes ACS vs pericarditis \n- Concurrent PR elevation in aVR suggests pericarditis instead of ACS. \n\n## Tricyclic antidepressant (TCA) \u0026 TCA-like overdose\n\n**Prominent R wave in aVR**\n\n![Example of a prominent R wave](https://aliemcards.netlify.com/media/ecg-lead-avr_image-3.png)\n\n- Classic ECG findings of TCA overdose:\n  - Sinus tachycardia\n  - Widened QRS and QTc interval\n  - Right axis deviation 130-170 degrees\n  - Prominent terminal R wave in aVR\n- Predictor of arrhythmia ([Buckley et al. Crit Care, 2003](http://www.ncbi.nlm.nih.gov/pubmed/12974977)):\n  - R/S ratio in aVR \u003e0.7 (PPV 46%, NPV 95%)\n\n## AVRT in Wolff-Parkinson-White (WPW)\n\n**Atroventricular reentry tachycardia**\n\n- ST elevation in aVR in narrow complex tachycardia\n- Narrow complex tachycardia ddx:\n  - AV node reentry tachycardia \n  - AV reentry tachycardia\n  - Atrial tachycardia\n- ST elevation in aVR suggestive more of AVRT in WPW (sensitivity 71%, specificity 70%)\n\n## Vereckei criteria: VT versus SVT in wide complex tachycardia\n\n**Vereckei criteria:** \n\n- Asks 4 questions. \n- More sensitive and specific to detect ventricular tachycardia (VT) than Brugada criteria.\n- **Criteria looks ONLY at lead aVR** (if answer is yes, then VT):\n\n1. Is there an initial R wave?\n2. Is there a r or q wave \u003e40 msec? (\u003e1 small box width)\n3. Is there a notch on the descending limb of a negative QRS complex?\n4. Measure the voltage change in the first (vi) and last 40 msec (vt). Is vi / vt \u0026lt;1?\n\n![Example of VT vs SVT](https://aliemcards.netlify.com/media/ecg-lead-avr_image-4.png)\n\n| Criteria | Sensitivity | Specificity | PPV | NPV |\n| -------- | :---------: | :---------: | :-: | :-: |\n| Brugada  |     89%     |     73%     | 92% | 67% |\n| Verecki  |     97%     |     75%     | 93% | 87% |\n\n([Vereckei et al, Heart Rhythm 2008](http://www.ncbi.nlm.nih.gov/pubmed/18180024))\n\n## References\n\n- Kireyev D et al.Clinical utility of aVR-The neglected electrocardiographic lead. Ann Noninvasive Electrocardiol. 2010;15(2):175-80. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20522059)]\n- Riera AR et al.Clinical value of lead aVR. Ann Noninvasive Electrocardiol. 2011 Jul;16(3):295-302. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21762258)]\n- Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm. 2008 Jan;5(1):89-98. doi: 10.1016/j.hrthm.2007.09.020. Epub 2007 Sep 20. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18180024)]\n- Buckley NA et. al.The limited utility of electrocardiography variables used to predict arrhythmia in psychotropic drug overdose.Crit Care. 2003 Oct;7(5):R101-7. Epub 2003 Aug 18. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12974977)]\n- Williamson K et al. Electrocardiographic applications of lead aVR. Am J Emerg Med. 2006 Nov;24(7):864-74. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17098112)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"ecg-lead-avr"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>